Analyst Price Targets — BVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 16, 2026 10:37 am | Caitlin Cronin | Canaccord Genuity | $15.00 | $8.60 | StreetInsider | Canaccord Reiterates Buy Rating on Bioventus Inc (BVS) |
| February 9, 2026 12:55 pm | — | Barrington | $13.00 | $8.51 | TheFly | Bioventus initiated with an Outperform at Barrington |
| May 7, 2025 1:16 pm | Chase Knickerbocker | Craig-Hallum | $15.00 | $6.20 | TheFly | Bioventus price target lowered to $15 from $17 at Craig-Hallum |
| October 1, 2024 1:38 pm | Caitlin Cronin | Canaccord Genuity | $12.00 | $11.79 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS) |
| August 7, 2024 9:05 am | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | TheFly | Bioventus price target raised to $12 from $9 at Craig-Hallum |
| May 7, 2024 1:38 pm | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | StreetInsider | Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity |
| March 13, 2024 8:42 am | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | StreetInsider | Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum |
| November 30, 2022 8:31 am | — | Goldman Sachs | $2.50 | $1.91 | Benzinga | Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5 |
Latest News for BVS
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BVS.
U.S. House Trading
No House trades found for BVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.